IOCB Tech

Boston is not just a location. It is a concentration of capital, experience, and decision-making. For Central European projects, that means a very different operating environment. Through @IOCBBoston, we are not starting from zero — we are already part of that ecosystem.

Join us at Bio€quity Europe 2026 for the Regional Host Panel: How to Bring Great Science to Market – The CEE Case. @julieinprague will join the discussion, moderated by @valkova_zuzana. 📅 5 May 🕓 4:00 pm #BioEquity #Biotech #TechTransfer #CEE

#BioVaria is in full swing, and we’re glad to be part of it in Munich. Great to be here with colleagues from i&i Prague, PharmTheon and other partners — with support from Lukáš Opatrný (Czech General Consulate) and Prague.bio helping strengthen the Czech presence.

BioVaria 2026 starts in Munich on Monday. Over two days, the event will bring together investors, innovators and tech transfer professionals from across Europe. IOCB Tech is proud to be a power partner and to contribute with five presentations. #BioVaria #LifeSciences #Biotech

Most projects do not fail because the science is weak. They fail in the space between discovery and use — where relevance, risk, and real-world fit become the real test. That middle layer may be less visible, but it is where projects become viable. #TechTransfer #Innovation

Some progress in life sciences comes from improving the methods science already relies on. Great to see LAM-X develop VerdiBlot and advance work on nanomaterials — a strong example of technical innovation in the layer that underpins experimental biology. #LifeSciences #Biotech

Bio€quity Europe is just around the corner — and this year, Prague will host it. From 4–6 May 2026, the event will bring investors, biotech companies, and tech transfer professionals together in Prague. For IOCB Tech, it is a valuable chance to strengthen links between research, investment, and application. #BioEquity #Biotech #TechTransfer

For more information, visit: verdiblot.com

Some of the biggest advances in life sciences are not therapies, but tools. Western blot, ELISA, PCR — methods that shape what scientists are able to see. Great to see LAM-X building on that logic with VerdiBlot, a new bioanalytical method for more reliable protein analysis. Congrats. #Bioanalysis #DrugDiscovery #LifeSciences #Biotech

Czechia does not underperform in research investment. Around 2% of GDP goes into R&D, and the scientific base is strong. The challenge comes later: turning research into companies, products, and real market presence. That is where IOCB Tech works — helping strong projects move from discovery toward application. #TechTransfer #Innovation #LifeSciences

🇵🇹 We’re delighted to be at BIO-Europe Spring in beautiful Lisbon, Portugal, alongside our colleagues from Prague.bio Come and meet us at BOOTH 73. 🤝🧬 For the next few days, this city is bringing together over 3,700 professional visitors and more than 2,000 exhibitors — and we’re very glad to be part of it. #BIOEuropeSpring #Lisbon #Biotech #LifeSciences #Networking #Innovation

🎧 Today’s question: Which biotech podcasts are actually worth listening to? Podcast listening is growing fast in the Czech Republic — weekly reach rose from 36% in 2023 to 44% in 2025. But does the same already apply to biotech? One tip from us: Martin Kovalčík from #i&i Prague interviewed Jan Berka, who helps develop the portfolio of i&i Prague projects, in a new episode of #ChemagazinTalks. 👉 Link in comments 📷 Photo: i&i Prague #Biotech #Podcast #TechTransfer

🤖AI in research is moving fast — and so are the legal & ethical questions around it. On February 25, 2026, our colleagues Matěj Malý and Kateřina Habelová represented IOCB Tech at an all-day seminar at the Pražský inovační institut focused on intellectual property management, AI, and ethics in science & research. Key topics included: ✅ Copyright, patents, and licensing in the context of AI ✅ Data protection and responsible data use ✅ Accountability for AI-generated outcomes ✅ The European AI Act and what it means for research and innovation 💬 “AI is already part of everyday life. It’s built into our phones, computers, and even the browsers we use. In science and translational research, it’s becoming more and more important, but it also raises some fundamental questions: who owns the work an AI produces, how safe our data really is, and what the legal rules are. These are serious issues, which is why my colleague and I attended an all-day seminar focused on them.” — Matěj Malý At IOCB Tech, we see AI as a powerful accelerator — but only when paired with clear rules, strong governance, and responsible practice. ✅ 📷 Photo credit: Pražský inovační institut #IntellectualProperty #IP #TechTransfer #AIAct #DataEthics #ResponsibleAI

Today, we’re happy to spotlight Jana Kenney, Analyst and Project Manager at IOCB Tech, and her take on why strong science alone isn’t enough. 💬“Scientists are sometimes locked in the belief that good science sells itself. In reality, a solid scientific background is a necessary prerequisite but in no way a guarantee of a project’s commercial success. Concerning the lay public, I think there is little awareness of what technology transfer actually means and how it is rendered in practice. It is perhaps time to change this view.” At IOCB Tech, we work every day at the intersection of excellent science and real-world impact — and Jana is a key part of making that bridge work. We really appreciate Jana’s strong instinct for what it takes to move projects forward beyond the lab. #MeetTheTeam — a closer look at the people who help turn great science into real-world impact. #TechnologyTransfer #LifeSciences #Biotech #Innovation

@PragueMetabol An important topic as metabolism research moves closer to clinical impact — looking forward to the discussions!

From energy and metabolic sensors to organellar signaling, autophagy, ageing, cancer metabolism, immunity & infections — bridging basic science with clinical insights. #MetabolismSymposium

Should biotech stay in the lab — or should it also help strengthen Europe’s security?🛡️ 💬 “Given the current geopolitical situation — globally and in our region — we in biotech can no longer afford to overlook the question of stability and safety,” says Matěj Malý, Project Manager at IOCB Tech. That’s exactly what we explored on February 17 during the morning Czech Industry Day and the afternoon EDF InfoDay Matchmaking. These two networking events aimed to strengthen IOCB Tech’s engagement with the defence & security sector and build the right partnerships for translational research. They also highlighted opportunities for cooperation within the European Defence Fund (EDF), with Matěj Malý and Julie Proft, Deputy CEO, representing IOCB Tech on-site. 🤝 💬 “It’s important to seek translational research opportunities also in the defence and security sector, where chemistry has significant natural overlap. Events like these help build a deeper understanding of how the defence ecosystem works — and support the creation of key contacts in this field.” — Matěj Malý 🔗 Event link: lnkd.in/dzt93UFs 🏛️ Organised by: Defence and Security Industry Association of the Czech Republic (AOBP) #Biotech #Defence #Security #EuropeanDefenceFund #Innovation #TechnologyTransfer

Throwback to our Czech delegation at @BioVaria 2025 🇨🇿 Proud that IOCB Tech is a Power Partner of BioVaria 2026 — we’ll be back in Munich on 27–28 Apr.📍 A curated 2-day showcase of dozens of licensable life-science technologies + selected start-ups, with partnering that actually leads to follow-ups. Register: biovaria.org/register-plan/… Who else is going? 🤝 #BioVaria #TechTransfer #LifeSciences #Biotech